Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics (NASDAQ:CRSP). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...

John Greene, a director at $CRSP, bought 7,000 shares of the company on 02-26-2025 for an estimated $313,947. This trade was reported by Quiver Quantitative using ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and a rating upgrade by a Wall Street analyst. Alongside earnings results ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session ... At the same time, the Dow added 0.38%, and the tech-heavy Nasdaq gained 0.98%. The company's shares have seen an increase of ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...